Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





PCR of Gargle Lavage Samples as Effective as Nasopharyngeal Swabs to Identify SARS-CoV-2 Infection, Finds Study

By LabMedica International staff writers
Posted on 30 Jul 2021
Twenty-six subjects from a cohort of 80 tested positive for SARS-CoV-2 via nasopharyngeal swab, and all 26 tested positive using gargle lavage (mouthwash), according to new research. More...


The detection method for testing samples used in this study by researchers from University of Konstanz (Konstanz, Germany) was the highly sensitive real time polymerase chain reaction (RT-PCR). Nasopharyngeal swabbing, currently the gold standard for collecting samples for COVID testing, has a low rate of acceptance due to the discomfort of having a nasal passage swabbed.

“Our results show that in all cases, where people were positively tested by the gold standard nasal swabbing, one could also detect the virus in gargle lavage by the same RT-PCR method,” said corresponding author Christof R. Hauck, PhD, professor of cell biology, Faculty of Natural Sciences, Department of Biology, University of Konstanz, Germany.
This sampling procedure can be conducted safely in a general practitioner’s office without extra protective equipment for physicians’ staff, as the patients themselves perform the sampling,” said Dr. Hauck. “We usually sent the patients with the gargle solution and sampling container outside.” There, they gargled in front of a window, observed by a physician’s staff member. Thus, “we need not expose trained personnel to the danger of taking samples from so many potentially infected people.”

Study subjects had typical respiratory symptoms or known contact with infected persons. Each received both a nasal swab administered by a professional health practitioner, “which was needed for the regular diagnostic procedure, and each self–performed a gargle lavage,” said Dr. Hauck. “These paired samples were then transferred to the central diagnostic lab, where they were analyzed in parallel, so that the results could be directly compared.”

“Besides performing diagnostics on symptomatic patients, we are involved in regular SARS-CoV-2 surveillance on our university campus, where we test people twice a week. As nasal swabbing is not very pleasant, we were looking for an alternative, and gargle lavage turned out to be highly accepted,” said Dr. Hauck.

“By finding complete congruence of results obtained with paired samples of a sizeable patient cohort, our results strongly support the idea that the painless self-collection of gargle lavage provides a suitable and uncomplicated source for reliable SARS-CoV-2 detection,” said Dr. Hauck.

Related Links:
University of Konstanz


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.